JP2024503379A5 - - Google Patents

Info

Publication number
JP2024503379A5
JP2024503379A5 JP2023541613A JP2023541613A JP2024503379A5 JP 2024503379 A5 JP2024503379 A5 JP 2024503379A5 JP 2023541613 A JP2023541613 A JP 2023541613A JP 2023541613 A JP2023541613 A JP 2023541613A JP 2024503379 A5 JP2024503379 A5 JP 2024503379A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
pharmaceutical composition
fucosyl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011564 external-priority patent/WO2022150557A1/en
Publication of JP2024503379A publication Critical patent/JP2024503379A/ja
Publication of JP2024503379A5 publication Critical patent/JP2024503379A5/ja
Pending legal-status Critical Current

Links

JP2023541613A 2021-01-08 2022-01-07 抗フコシルgm1抗体を使用した組み合わせ療法 Pending JP2024503379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
US63/135,479 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (2)

Publication Number Publication Date
JP2024503379A JP2024503379A (ja) 2024-01-25
JP2024503379A5 true JP2024503379A5 (cg-RX-API-DMAC7.html) 2025-01-08

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541613A Pending JP2024503379A (ja) 2021-01-08 2022-01-07 抗フコシルgm1抗体を使用した組み合わせ療法

Country Status (10)

Country Link
US (1) US20240050564A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274850A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024503379A (cg-RX-API-DMAC7.html)
KR (1) KR20230129467A (cg-RX-API-DMAC7.html)
CN (1) CN116745322A (cg-RX-API-DMAC7.html)
AU (1) AU2022205648A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204392A1 (cg-RX-API-DMAC7.html)
IL (1) IL304200A (cg-RX-API-DMAC7.html)
MX (1) MX2023007780A (cg-RX-API-DMAC7.html)
WO (1) WO2022150557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members
WO2026107143A1 (en) * 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Fixed dose combination of anti-fucosyl-gm1 antibody and anti-pd-1 antibody and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US11104739B2 (en) * 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
WO2017210631A1 (en) * 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
SG11201909064RA (en) * 2017-03-30 2019-10-30 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
TWI890148B (zh) * 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法

Similar Documents

Publication Publication Date Title
JP2020002171A5 (cg-RX-API-DMAC7.html)
US11591406B2 (en) Treatment for multiple myeloma (MM)
JP2021523122A5 (cg-RX-API-DMAC7.html)
JP2022548947A5 (cg-RX-API-DMAC7.html)
JP2022525164A5 (cg-RX-API-DMAC7.html)
JP2021535161A5 (cg-RX-API-DMAC7.html)
JP2021528438A5 (cg-RX-API-DMAC7.html)
JP2019524820A5 (cg-RX-API-DMAC7.html)
IL320562A (en) Cancer treatment methods
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2025512785A5 (cg-RX-API-DMAC7.html)
JP2021532176A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2021501776A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2023524359A5 (cg-RX-API-DMAC7.html)
JP2021523138A5 (cg-RX-API-DMAC7.html)
JP2025511167A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2022514561A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2021530502A5 (cg-RX-API-DMAC7.html)
JP2023500480A5 (cg-RX-API-DMAC7.html)
Miyata et al. Rebamipide enemas–new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis